<p>Bharat Biotech expects to receive significant data on its intranasal vaccine for Covid-19 in the next two and a half months, founder Krishna Ella has said.</p>.<p>However, Dr Ella did not give a specific timeline for the vaccine whose clinical trials are under way. "It is also easy to scale it up... can produce 100 million doses a month," he was <a href="https://www.thehindu.com/news/national/significant-data-on-nasal-vaccine-likely-in-25-months-krishna-ella/article35605714.ece" target="_blank">quoted as saying</a> during a FICCI Capital Markets Conference.</p>.<p>He also called on citizens to display Covid-appropriate behaviour, adding that if no other epidemic comes up until Diwali, "we are through as a country". </p>.<p>An intranasal vaccine will not only be simple to administer but also reduce the use of medical consumables such as needles, syringes, etc, significantly impacting the overall cost of a vaccination drive, he had said.</p>.<p>BBV154's (intranasal Covid-19 vaccine) pre-clinical testing has been completed for toxicology, immunogenicity and challenge studies. These studies have been conducted in the USA and India. </p>.<p>"The company is also seeking permission to conduct trials of a combination of Covaxin and the nasal vaccine. We have applied for clinical trial permission," he said during the event.</p>
<p>Bharat Biotech expects to receive significant data on its intranasal vaccine for Covid-19 in the next two and a half months, founder Krishna Ella has said.</p>.<p>However, Dr Ella did not give a specific timeline for the vaccine whose clinical trials are under way. "It is also easy to scale it up... can produce 100 million doses a month," he was <a href="https://www.thehindu.com/news/national/significant-data-on-nasal-vaccine-likely-in-25-months-krishna-ella/article35605714.ece" target="_blank">quoted as saying</a> during a FICCI Capital Markets Conference.</p>.<p>He also called on citizens to display Covid-appropriate behaviour, adding that if no other epidemic comes up until Diwali, "we are through as a country". </p>.<p>An intranasal vaccine will not only be simple to administer but also reduce the use of medical consumables such as needles, syringes, etc, significantly impacting the overall cost of a vaccination drive, he had said.</p>.<p>BBV154's (intranasal Covid-19 vaccine) pre-clinical testing has been completed for toxicology, immunogenicity and challenge studies. These studies have been conducted in the USA and India. </p>.<p>"The company is also seeking permission to conduct trials of a combination of Covaxin and the nasal vaccine. We have applied for clinical trial permission," he said during the event.</p>